Leukemia/Lymphoma Phenotyping by Flow Cytometry
2008003
Ordering Recommendation
Aids in the diagnosis of hematopoietic neoplasms.
Mnemonic
L/L PANEL
Methodology
Flow Cytometry
Performed
Sun-Sat
Reported
1-2 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Bone marrow. Whole blood: Green (sodium heparin), lavender (EDTA), or pink (K2EDTA). Tissue or fluid.  
Specimen Preparation
Transport 1 mL heparinized bone marrow (Min: 0.5 mL*) OR 5 mL whole blood (Min: 1mL*) OR 100 mg fresh tissue suspended in tissue culture media (e.g., RPMI 1640)
(Min: 100 mg*) OR 10-100 mL fresh fluid (Min: 3 mL*).*Minimum volume is dependent on cellularity.  
Storage/Transport Temperature
Specimen should be received within 24 hours of collection for optimal cell viability.
Bone marrow or whole blood:
Room temperature. Also acceptable: Refrigerated.
Tissue or fluid:
Refrigerated.  
Unacceptable Conditions
Unacceptable Conditions: Frozen, clotted or hemolyzed specimens.  
Remarks
A minimum of 10,000 viable cells is required for flow cytometry phenotyping of samples containing a very limited number of markers (may also be called antibodies or antigens). For low-count specimens, supplying clinical and diagnostic
information is especially important to help ensure that the most appropriate marker combinations are evaluated before the specimen is depleted of cells.
Bone marrow or whole blood:
Provide specimen source, CBC, Wright stained smear (if available), clinical history, differential diagnosis, and any relevant pathology reports.
Tissue or fluid:
Provide specimen source, clinical history, differential diagnosis, and any relevant pathology reports.
Follow up:
If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.  
Stability
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By Report  
Interpretive Data
By Report

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
 
Note
Flow cytometric leukemia and lymphoma analysis may aid in identifying the tumor lineage for diagnostic and prognostic purposes. After review of the clinical history and morphology, a panel of markers is selected for each case by a board-certified pathologist. In most cases, the lineage can be identified as T-cell, B-cell, or myeloid and a diagnosis or differential diagnosis can be made. 

Available Markers*:

T-cell:
CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3
B-cell:
CD10, CD19, CD20, CD22, CD23, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda
Myelo/Mono:
CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase
Misc:
CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2, ALK-1, CD123, CD138, CD200, CD26, CD45.

*Not all markers will be reported in all cases.
Requests for specific markers to be run must be listed on manual requisition or by footnote for electronic orders. We do not offer individual marker identification separately outside of the markers in this panel.

A comprehensive flow cytometric Leukemia/Lymphoma assessment of tissue, fluid, or peripheral blood typically includes 15 or more markers; a bone marrow evaluation typically includes 22 or more markers. At the discretion of the pathologist, limited-cellularity samples (CSF, tissue/fluids) will be triaged and an appropriate number of markers will be run due to the irreplaceable nature of these samples. Limited-cellularity samples typically include a minimum number of markers (e.g., 7-15 markers).

The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers, 9-15 markers, and 16+ markers interpreted. Charges apply per marker.
CPT Code(s)
88184, 88185 each additional marker; 88187 or 88188 or 88189.
Components
Component Test Code*Component Chart NameLOINC
0092286Number Of Markers19099-1
2008004Leuk/Lymph Phenotype, % CD220594-8
2008005Leuk/Lymph Phenotype, % CD320599-7
2008006Leuk/Lymph Phenotype, % CD4 
2008007Leuk/Lymph Phenotype, % CD520611-0
2008008Leuk/Lymph Phenotype, % CD720612-8
2008009Leuk/Lymph Phenotype, % CD8 
2008010Leuk/Lymph Phenotype, % CD2532495-4
2008011Leuk/Lymph Phenotype, % Alpha-Beta32860-9
2008012Leuk/Lymph Phenotype, % Gamma-Delta32861-7
2008013Leuk/Lymph Phenotype, % CD120586-4
2008014Leuk/Lymph Phenotype, % Cytoplasmic CD332857-5
2008015Leuk/Lymph Phenotype, % CD1626560-3
2008016Leuk/Lymph Phenotype, % CD5621166-4
2008017Leuk/Lymph Phenotype, % CD5732498-8
2008018Leuk/Lymph Phenotype, % CD1020587-2
2008019Leuk/Lymph Phenotype, % CD1920593-0
2008020Leuk/Lymph Phenotype, % CD2020595-5
2008021Leuk/Lymph Phenotype, % CD2138419-8
2008022Leuk/Lymph Phenotype, % CD2220596-3
2008023Leuk/Lymph Phenotype, % CD2319078-5
2008024Leuk/Lymph Phenotype, % CD2420597-1
2008025Leuk/Lymph Phenotype, % Kappa20617-7
2008026Leuk/Lymph Phenotype, % Lambda20618-5
2008027Leuk/Lymph Phenotype, % CD10326556-1
2008028Leuk/Lymph Phenotype, % CD11c21154-0
2008029Leuk/Lymph Phenotype, % FMC721171-4
2008030Leuk/Lymph Phenotype, % Cyto Kappa 
2008031Leuk/Lymph Phenotype, % Cyto Lambda 
2008032Leuk/Lymph Phenotype, % bcl-232757-7
2008033Leuk/Lymph Phenotype, % CD3020600-3
2008034Leuk/Lymph Phenotype, % CD3420602-9
2008035Leuk/Lymph Phenotype, % HLA-DR32751-0
2008036Leuk/Lymph Phenotype, % CD11b32758-5
2008037Leuk/Lymph Phenotype, % CD1320588-0
2008038Leuk/Lymph Phenotype, % CD14 (MO2) 
2008039Leuk/Lymph Phenotype, % CD14 (MY4) 
2008040Leuk/Lymph Phenotype, % CD1520590-6
2008041Leuk/Lymph Phenotype, % CD1838170-7
2008042Leuk/Lymph Phenotype, % CD3320601-1
2008043Leuk/Lymph Phenotype, % CD6432747-8
2008044Leuk/Lymph Phenotype, % CD11732742-9
2008045Leuk/Lymph Phenotype, % Myeloperoxidase32759-3
2008046Leuk/Lymph Phenotype, % CD951374-7
2008047Leuk/Lymph Phenotype, % CD4120608-6
2008048Leuk/Lymph Phenotype, % CD42b51325-9
2008049Leuk/Lymph Phenotype, % CD6121167-2
2008050Leuk/Lymph Phenotype, % Glycophorin32750-2
2008051Leuk/Lymph Phenotype, % CD3820603-7
2008052Leuk/Lymph Phenotype, % TdT38435-4
2008053Leuk/Lymph Phenotype, % ALK-1 
2008054Leuk/Lymph Phenotype, % CD12351045-3
2008055Leuk/Lymph Phenotype, % CD13832743-7
2008056Leuk/Lymph Phenotype, % CD200 
2008057Leuk/Lymph Phenotype, % CD2617127-2
2008058Leuk/Lymph Phenotype, % CD4520610-2
2008059Leuk/Lymph Phenotype, Impression45267-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chronic Lymphocytic Leukemia Follow up Phenotyping by Flow Cytometry
  • Follow-Up Phenotyping
  • Hematopoietic neoplasms monitoring
  • Leukemia/Lymphoma Evaluation Panel
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Bone Marrow
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Miscellaneous
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Whole Blood
  • Neoplastic Mature T-Cell Evaluation by Flow Cytometry